Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
July 2012, Vol 3, No 5
July 2012, Vol 3, No 5
Tough Times for Small Oncology Practices
By
Caroline Helwick
July 2012, Vol 3, No 5
Houston, TX—Hard times are getting even tougher for small oncology practices, said Leonard Natelson, Chief Executive Officer, Hematology/Oncology Associates, Rockland, NY, at the Second Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Involving the Patient in End-of-Life Care Decisions: Aetna’s Oncology Strategy
By
Caroline Helwick
End-of-Life Care
,
Policies & Guidelines
July 2012, Vol 3, No 5
Houston, TX—Payer-sponsored programs that promote appropriate end-of-life care are beneficial to all stakeholders, according to Ira M. Klein, MD, MBA, Chief of Staff to the Chief Medical Officer, Aetna Oncology Strategy.
Read Article
Collaborate, Coordinate to Achieve Value in Oncology
July 2012, Vol 3, No 5
Houston, TX—“Collaboration, coordination, data, and innovation are key to achieving value-based cancer care,” said Loreen M. Brown, MSW, Vice President of Reimbursement and Access Consulting, Xcenda, AmerisourceBergen Consulting Services.
Read Article
Evidence-Based Guidelines/Pathways Critical for Value-Based Benefit Design in Oncology
By
Caroline Helwick
July 2012, Vol 3, No 5
Houston, TX—There is no question that evidence-based guidelines and pathways are critical to the success of value-based oncology, but not all stakeholders have an equal voice, said Craig Deligdish, MD, Chief Medical Officer at Oncology Resource Networks of America at the Second Annual Meeting of the Association for Value-Based Cancer Care.
Read Article
Chemotherapy-Related Toxicity Adds to Economic Burden in Metastatic Breast Cancer
By
Caroline Helwick
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—Adverse events (AEs) related to chemotherapy for metastatic breast cancer create a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said lead investigator Sara A. Hurvitz, MD, Director of the Oncology Breast Can cer Program at University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center and Assistant Clinical Professor at UCLA School of Medicine, who presented an economic analysis at the 2012 Ameri can Society of Clinical Oncology meeting.
Read Article
Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma
By
Wayne Kuznar
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Tivozanib, a potent investigational tyrosine kinase inhibitor with a long half-life, demonstrated significant improvement in progression-free survival (PFS) as first-line targeted therapy for metastatic renal-cell carcinoma (RCC), according to results from a phase 3 randomized, open-label trial.
Read Article
Endocrine Therapy Substantially Underutilized Among Low-Income Patients with Breast Cancer
By
Caroline Helwick
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—Researchers from the University of North Carolina in Chapel Hill reported at the 2012 American Society of Clinical Oncology meeting that endocrine therapy is substantially underutilized among the low-income breast cancer population.
Read Article
Cancer Screening Saves Lives, Is Cost-Effective
By
Wayne Kuznar
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—Improved cancer screening can save lives, and despite the high cost of implementing such a measure, it was found cost-effective and therefore valuable in a recent analysis using quality-adjusted life-years (QALYs), said Michael S. Broder, MD, President of Partnership for Health Analytic Research, LLC (PHAR), CA, and colleagues, at the 2012 American Society of Clinical Oncology meeting.
Read Article
Patients Willing to Pay Out of Pocket for Genetic Testing to Assess Colorectal Cancer Risk
By
Audrey Andrews
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—In a cohort of patients at risk for colorectal cancer (CRC), the majority were willing to pay some out-of-pocket (OOP) expenses for genetic testing, Fox Chase Cancer Center researchers reported in a poster that was presented at the 2012 American Society of Clinical Oncology (ASCO) meeting and earned an ASCO Merit Award.
Read Article
High OOP Costs for Medicare Patients with Cancer
By
Mark Knight
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—Older patients with cancer and Medicare coverage often incur greater out-of-pocket (OOP) expenses compared with their counterparts without cancer.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma